homepage-top-section

GlaxoSmithKline (GSK) has announced plans to construct a new campus for biotechnology and early-stage life science companies in Stevenage, England. The company is looking for a development partner

Regeneron has announced plans to invest about $1.8bn to expand its facilities at its Westchester County campus in the US, over the next six years. The company intends

Eli Lilly and Company is set to acquire the remaining shares of biotech firm Protomer Technologies in a deal valued more than $1bn. The latest move follows Lilly’s

The Russian Direct Investment Fund (RDIF) has collaborated with Serum Institute of India (SII) to produce Sputnik V Covid-19 vaccine in India. RDIF and SII plan to produce

Danish pharma company Novo Nordisk has agreed to acquire Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme for a deal valued at $1.2bn. Under the terms

Philip Morris International (PMI) has agreed to acquire British pharmaceutical firm Vectura Group for about $1.183bn (£852m) to expand its product pipeline development capabilities in inhaled therapeutics. The

Verge Genomics has announced a three-year partnership with Eli Lilly and Company to discover and develop novel therapies for amyotrophic lateral sclerosis (ALS), a motor neuron disease. As

Altesa Biosciences has signed an exclusive worldwide license agreement with biotechnology firm Vaxart for the development and commercialisation of the latter’s patented formulation of the capsid-binding Vapendavir antiviral.

The European Commission has cleared AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39bn. This marks an ‘important step’ towards the completion of the acquisition, which was first announced